Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4307817 | 0.80 | KCNH2 (0.43) | KCNH2MAPK13CSNK1DCSNK1EMAPK12 | |
| SCHEMBL10061638 | 0.78 | KDM1A (0.49) | KCNH2MAPK13CSNK1DCSNK1EMAPK12 | |
| SCHEMBL31416644 | 0.77 | — | — | |
| SCHEMBL539467 | 0.77 | — | — | |
| SCHEMBL30001281 | 0.77 | NPSR1 (0.50) | KDM4ECYP1A2CYP3A4MAPTCYP2C9 | |
| SCHEMBL15543495 | 0.77 | NPSR1 (0.50) | KDM4ECYP1A2CYP3A4MAPTCYP2C9 | |
| SCHEMBL21527214 | 0.76 | NOS3 (0.52) | KCNH2MAPK13CSNK1DCSNK1EMAPK12 | |
| SCHEMBL10061637 | 0.76 | MAPK13 (0.40) | KCNH2MAPK13CSNK1DCSNK1EMAPK12 | |
| SCHEMBL29705247 | 0.76 | KDM4E (0.38) | KDM4ECYP1A2CYP3A4MAPTCYP2C9 | |
| SCHEMBL1050596 | 0.76 | KDM4E (0.38) | KDM4ECYP1A2CYP3A4MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2021155321-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| EP-3083583-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF | SAGIMET BIOSCIENCES INC (US) | 2020-11-18 | — | — | EP | disclosed |
| WO-2020160180-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| US-10428043-B2 | Green oxidation catalytic system | TRUSTEES OF BOSTON UNIVERSITY (US) | 2019-10-01 | — | — | US | disclosed |
| EP-2870150-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3 V BIOSCIENCES INC (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20180297976-A1 | GREEN OXIDATION CATALYTIC SYSTEM | TRUSTEES OF BOSTON UNIVERSITY (US) | 2018-10-18 | — | — | US | disclosed |
| US-20180222892-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| WO-2016100850-A2 | GREEN OXIDATION CATALYTIC SYSTEM | TRUSTEES OF BOSTON UNIVERSITY (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222892-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | KCNH2 4622/4885MAPK13 1951/4885CSNK1D 2915/4885 |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | KCNH2 4135/4885MAPK13 3569/4885CSNK1D 1748/4885 |
| US-10428043-B2 | Green oxidation catalytic system | TKT, OGDH, SOD1 | KCNH2 671/4885MAPK13 2891/4885CSNK1D 1777/4885 |
| US-20180297976-A1 | GREEN OXIDATION CATALYTIC SYSTEM | TKT, OGDH, SOD1 | KCNH2 671/4885MAPK13 2891/4885CSNK1D 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.